Olubunmi Oladunjoye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olubunmi Oladunjoye has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Adeolu Oladunjoye
Boston Childrens Hosp, Crit Care Med, Boston, MA USA
8 shared publications Adeolu Oladunjoye
4 shared publications- Ibiyemi O Oke
Reading Hosp Tower Hlth, Internal Med, W Reading, PA 19611 USA
4 shared publications - Eduardo D. Espiridion
Psychiatry, Drexel University College of Medicine, Philadelphia, USA
3 shared publications - Maria Ruiza Yee
Psychiatry, Drexel University College of Medicine, Philadelphia, USA
3 shared publications - Oreoluwa Oladiran
Reading Hospital, Tower Health System, West Reading, PA, USA
3 shared publications
Latest Publications
- Open Access
A comparison of the association of fat-to-muscle ratio vs. BMI and hypertension: A US population-based study
Objective: Hypertension is the leading cause of preventable cardiovascular disease (CVD) and is associated with obesity. Body mass index (BMI), the most common measure of obesity, does not distinguish between fat and muscle mass. By contrast, dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring fat composition with high accuracy and minimal variability. To our knowledge, no United States studies have examined the association between BMI or fat-to-muscle-ratio (FTMR) (using DXA) and hypertension. Methods: We analyzed NHANES data of adults aged 20-59 years from 5 consecutive cycles (2011-2012 through 2017-2018). The primary outcome was hypertension. Logistic regression was used to determine the associations between FTMR and odds of hypertension, and between BMI and hypertension. Results: The mean FTMR was higher in the hypertension compared to the non-hypertension group (0.57 ± 0.01 vs. 0.53 ± 0.004, p < 0.001), with a similar pattern observed for BMI (32.3 ± 0.2 vs. 28.1 ± 0.1, p < 0.001). Logistic regression analysis showed each one-unit increase in FTMR was associated with 2.80 times higher odds of hypertension, while each 1 kg/m² increase in BMI was associated with 1.08 times higher odds. The sex specific odds ratio (OR) for FTMR were even higher after adjusting for age (males 24.58 (11.74-51.46), females 8.77 (5.04-15.26), p<0.001). However, after adjusting for sex in a receiver operator curve (ROC) analysis, FTMR (Area Under the Curve [AUC] 0.63; 95% CI 0.62–0.64) did not outperform BMI (AUC 0.67; 95% CI 0.66–0.68) regarding their association with hypertension. Conclusion: Although logistic regression showed a stronger relation of FTMR than BMI and the odds of hypertension, the ROC curve indicated no difference in association of hypertension and FTMR and BMI. Further research should examine the ability of FTMR compared to BMI to predict hypertension and CVD related-complications in high-risk subgroups.
Open AccessA comparison of the association of fat-to-muscle ratio vs. BMI and hypertension: A US population-based study
Objective: Hypertension is the leading cause of preventable cardiovascular disease (CVD) and is associated with obesity. Body mass index (BMI), the most common measure of obesity, does not distinguish between fat and muscle mass. By contrast, dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring fat composition with high accuracy and minimal variability. To our knowledge, no United States studies have examined the association between BMI or fat-to-muscle-ratio (FTMR) (using DXA) and hypertension. Methods: We analyzed NHANES data of adults aged 20-59 years from 5 consecutive cycles (2011-2012 through 2017-2018). The primary outcome was hypertension. Logistic regression was used to determine the associations between FTMR and odds of hypertension, and between BMI and hypertension. Results: The mean FTMR was higher in the hypertension compared to the non-hypertension group (0.57 ± 0.01 vs. 0.53 ± 0.004, p < 0.001), with a similar pattern observed for BMI (32.3 ± 0.2 vs. 28.1 ± 0.1, p < 0.001). Logistic regression analysis showed each one-unit increase in FTMR was associated with 2.80 times higher odds of hypertension, while each 1 kg/m² increase in BMI was associated with 1.08 times higher odds. The sex specific odds ratio (OR) for FTMR were even higher after adjusting for age (males 24.58 (11.74-51.46), females 8.77 (5.04-15.26), p<0.001). However, after adjusting for sex in a receiver operator curve (ROC) analysis, FTMR (Area Under the Curve [AUC] 0.63; 95% CI 0.62–0.64) did not outperform BMI (AUC 0.67; 95% CI 0.66–0.68) regarding their association with hypertension. Conclusion: Although logistic regression showed a stronger relation of FTMR than BMI and the odds of hypertension, the ROC curve indicated no difference in association of hypertension and FTMR and BMI. Further research should examine the ability of FTMR compared to BMI to predict hypertension and CVD related-complications in high-risk subgroups.
- Open Access
- 1 March 2023
- Published by Tower Health in Transformative Medicine
- Vol. 2 (1) , 6-9
Delay in diagnosis of PD-1 Inhibitor induced Secondary adrenal Insufficiency
Introduction: Immune checkpoint inhibitors including PD-1 inhibitors, were initially approved for the treatment of metastatic melanoma but are now increasingly being used for different types of solid organ malignancies. Despite the important clinical benefits, they are associated with immune-related adverse events. The most critical endocrinopathy associated with PD -1 inhibitor is adrenal insufficiency (AI), which requires prompt diagnosis and management to avoid fatality. Case presentation: We present the case of a 78-year-old woman with colon adenocarcinoma treated with Nivolumab (PD-1 inhibitor) after her pulmonary metastases progressed on chemotherapy. She presented to the hospital with progressive generalized weakness, fatigue, headache, lightheadedness, nausea, myalgia, reduced oral intake. She had 2 prior hospitalizations on account of similar symptoms with workup negative for cancer progression or gastrointestinal obstruction. Her laboratory values showed Na 128mmol/L, K 3.4mmol/L, Cr 0.52mg/dL and blood sugar 42mg/dL. Morning cortisol was low at 2.2µg/dL and ACTH stimulation test was positive. She was diagnosed with AI secondary to Nivolumab use and was started on Hydrocortisone while Nivolumab was discontinued. Conclusion: Immune checkpoint inhibitors have a unique side effect profile of immune-related adverse events, the most critical of which is AI. However, the non-specific manifestations of AI can lead to misdiagnosis or delay in diagnosis. Therefore, it is important for physicians to have high index suspicion for AI in acutely ill patients on PD-1 inhibitors for prompt recognition, diagnosis and treatment of AI which is important to prevent life-threatening adrenal crisis.
- 1 March 2023
- Published by Tower Health in Transformative Medicine
- Vol. 2 (1) , 6-9
Open AccessDelay in diagnosis of PD-1 Inhibitor induced Secondary adrenal Insufficiency
Introduction: Immune checkpoint inhibitors including PD-1 inhibitors, were initially approved for the treatment of metastatic melanoma but are now increasingly being used for different types of solid organ malignancies. Despite the important clinical benefits, they are associated with immune-related adverse events. The most critical endocrinopathy associated with PD -1 inhibitor is adrenal insufficiency (AI), which requires prompt diagnosis and management to avoid fatality. Case presentation: We present the case of a 78-year-old woman with colon adenocarcinoma treated with Nivolumab (PD-1 inhibitor) after her pulmonary metastases progressed on chemotherapy. She presented to the hospital with progressive generalized weakness, fatigue, headache, lightheadedness, nausea, myalgia, reduced oral intake. She had 2 prior hospitalizations on account of similar symptoms with workup negative for cancer progression or gastrointestinal obstruction. Her laboratory values showed Na 128mmol/L, K 3.4mmol/L, Cr 0.52mg/dL and blood sugar 42mg/dL. Morning cortisol was low at 2.2µg/dL and ACTH stimulation test was positive. She was diagnosed with AI secondary to Nivolumab use and was started on Hydrocortisone while Nivolumab was discontinued. Conclusion: Immune checkpoint inhibitors have a unique side effect profile of immune-related adverse events, the most critical of which is AI. However, the non-specific manifestations of AI can lead to misdiagnosis or delay in diagnosis. Therefore, it is important for physicians to have high index suspicion for AI in acutely ill patients on PD-1 inhibitors for prompt recognition, diagnosis and treatment of AI which is important to prevent life-threatening adrenal crisis.
- Open Access
- 2 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e31959
Renal diseases associated with multiple sclerosis: A narrative review
The mechanisms of renal pathology in multiple sclerosis (MS) can be related to the disease itself or its treatment. Although kidney disease can be associated with MS, not much has been reported in the literature; hence, our study aimed to describe the prevalence and types of renal diseases and discuss their prognosis in patients with MS. A literature search (2012–2022) was performed using the Scale for the Assessment of Narrative Review Articles. The databases searched included MEDLINE (PubMed) and EMBASE. Fourteen articles from these databases met the inclusion criteria. The inclusion criteria were as follows: publications with full-text access. Articles published in English. Original articles related to renal diseases in MS. The prevalence of renal diseases in MS from the articles obtained ranged from 0.74% to 2.49%. Interferon beta (IFN-β)-associated glomerulonephritis was common among the reviewed articles. Significant improvement and resolution of the pathology were observed after the discontinuation of the offending medication. Renal symptoms in 2 out of 4 cases with renal thrombotic microangiopathy (TMA) induced by interferon-beta progressed to chronic kidney disease, even after the drug was stopped. Other studied renal pathologies included nephrolithiasis secondary to urinary retention and urinary catheter use in patients with MS.
- 2 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e31959
Open AccessRenal diseases associated with multiple sclerosis: A narrative review
The mechanisms of renal pathology in multiple sclerosis (MS) can be related to the disease itself or its treatment. Although kidney disease can be associated with MS, not much has been reported in the literature; hence, our study aimed to describe the prevalence and types of renal diseases and discuss their prognosis in patients with MS. A literature search (2012–2022) was performed using the Scale for the Assessment of Narrative Review Articles. The databases searched included MEDLINE (PubMed) and EMBASE. Fourteen articles from these databases met the inclusion criteria. The inclusion criteria were as follows: publications with full-text access. Articles published in English. Original articles related to renal diseases in MS. The prevalence of renal diseases in MS from the articles obtained ranged from 0.74% to 2.49%. Interferon beta (IFN-β)-associated glomerulonephritis was common among the reviewed articles. Significant improvement and resolution of the pathology were observed after the discontinuation of the offending medication. Renal symptoms in 2 out of 4 cases with renal thrombotic microangiopathy (TMA) induced by interferon-beta progressed to chronic kidney disease, even after the drug was stopped. Other studied renal pathologies included nephrolithiasis secondary to urinary retention and urinary catheter use in patients with MS.
- 7 November 2022
- Published by Elsevier in Annals of Epidemiology
- Vol. 75, 80
Racial disparities in COVID 19 case fatality in the US from 2020 to 2022
- 7 November 2022
- Published by Elsevier in Annals of Epidemiology
- Vol. 75, 80
Racial disparities in COVID 19 case fatality in the US from 2020 to 2022
- Open Access
- 7 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Rapidly Progressive Granulomatous Amoebic Encephalitis in a Diabetic Individual
We present a case of rapidly progressive granulomatous amoebic encephalitis caused by Balamuthia mandrillaris in an individual with diabetes mellitus. Our patient presented with occipital headache, blurry vision, confusion, and gait imbalance of one week's duration. Brain imaging revealed numerous peripheral ring-enhancing lesions concerning malignancy. Brain biopsy was consistent with Balamuthia mandrillaris infection. He passed away 45 days after presentation despite being treated with a five-drug regimen. This case highlights the importance of considering amoebic brain infections, especially with ring-enhancing lesions on imaging. There are opportunities to design modalities for rapid diagnosis and better treatment.
- 7 November 2021
- Published by Springer Nature in Cureus
- Vol. 13 (11)
Open AccessRapidly Progressive Granulomatous Amoebic Encephalitis in a Diabetic Individual
We present a case of rapidly progressive granulomatous amoebic encephalitis caused by Balamuthia mandrillaris in an individual with diabetes mellitus. Our patient presented with occipital headache, blurry vision, confusion, and gait imbalance of one week's duration. Brain imaging revealed numerous peripheral ring-enhancing lesions concerning malignancy. Brain biopsy was consistent with Balamuthia mandrillaris infection. He passed away 45 days after presentation despite being treated with a five-drug regimen. This case highlights the importance of considering amoebic brain infections, especially with ring-enhancing lesions on imaging. There are opportunities to design modalities for rapid diagnosis and better treatment.
- Open Access
- 2 November 2021
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 11 (6) , 747-752
Mortality due to COVID-19 infection: A comparison of first and second waves
The USA suffered an initial wave of COVID-19 cases from March to July in 2020. Cases again surged in August 2020 as business restrictions were lifted. We aimed to describe demographic, treatment, a...
- 2 November 2021
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 11 (6) , 747-752
Open AccessMortality due to COVID-19 infection: A comparison of first and second waves
The USA suffered an initial wave of COVID-19 cases from March to July in 2020. Cases again surged in August 2020 as business restrictions were lifted. We aimed to describe demographic, treatment, a...
- Open Access
- 10 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non- Alcoholic Fatty Liver Disease in Non-Obese Population
Background Non-alcoholic fatty liver disease (NAFLD), one of the leading causes of end-stage liver disease, is known to be associated with obesity. However, only a few studies in the United States (US) have described non-obese NAFLD, most of which were on the outpatient population. Aim We aimed to investigate the proportion of hospitalizations in the US with a diagnosis code that included NAFLD in the non-obese population. Methods We analyzed adult discharges from the Nationwide Inpatient Sample with a diagnosis of NAFLD from January 2010 to December 2014. We created two groups: obese (overweight or obese) and non-obese (normal or underweight) groups. Basic demographic and clinical characteristics were compared using the chi-square test and Student's t-test. Results A total of 194,787 hospitalizations with NAFLD were identified over the five-year period. It was observed that the prevalence of non-obese NAFLD hospitalizations increased yearly. Non-obese NAFLD hospitalizations had a higher mean age (57.5 vs 51.5 years, p < 0.0001) and a higher proportion of males (43.3% vs 36.1%, p < 0.0001) than obese NAFLD hospitalizations. With univariate analysis, non-obese NAFLD hospitalizations had lower odds of hypertension (OR 0.74, p < 0.0001), diabetes mellitus (OR 0.65, p < 0.0001). Non-obese hospitalizations had higher odds of cirrhosis (OR 1.30, p < 0.001) and decompensated cirrhosis (OR 1.30, p < 0.001) after adjusting for age, sex, race, diabetes mellitus, and dyslipidemia. Hospitalizations with non-obese NAFLD had higher odds of death (OR 1.49, p < 0.001) after adjusting for age, gender, race, co-morbidities, cirrhosis, and liver decompensation. Conclusion There is a continued rise in the proportion of non-obese NAFLD among hospitalizations in the US. Nonobese NAFLD hospitalizations were less likely to have hypertension and diabetes, but more likely to have decompensated liver disease. Further studies are needed to better characterize these patients to enable early detection, treatment, and reduction in complications of liver disease.
- 10 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessA Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non- Alcoholic Fatty Liver Disease in Non-Obese Population
Background Non-alcoholic fatty liver disease (NAFLD), one of the leading causes of end-stage liver disease, is known to be associated with obesity. However, only a few studies in the United States (US) have described non-obese NAFLD, most of which were on the outpatient population. Aim We aimed to investigate the proportion of hospitalizations in the US with a diagnosis code that included NAFLD in the non-obese population. Methods We analyzed adult discharges from the Nationwide Inpatient Sample with a diagnosis of NAFLD from January 2010 to December 2014. We created two groups: obese (overweight or obese) and non-obese (normal or underweight) groups. Basic demographic and clinical characteristics were compared using the chi-square test and Student's t-test. Results A total of 194,787 hospitalizations with NAFLD were identified over the five-year period. It was observed that the prevalence of non-obese NAFLD hospitalizations increased yearly. Non-obese NAFLD hospitalizations had a higher mean age (57.5 vs 51.5 years, p < 0.0001) and a higher proportion of males (43.3% vs 36.1%, p < 0.0001) than obese NAFLD hospitalizations. With univariate analysis, non-obese NAFLD hospitalizations had lower odds of hypertension (OR 0.74, p < 0.0001), diabetes mellitus (OR 0.65, p < 0.0001). Non-obese hospitalizations had higher odds of cirrhosis (OR 1.30, p < 0.001) and decompensated cirrhosis (OR 1.30, p < 0.001) after adjusting for age, sex, race, diabetes mellitus, and dyslipidemia. Hospitalizations with non-obese NAFLD had higher odds of death (OR 1.49, p < 0.001) after adjusting for age, gender, race, co-morbidities, cirrhosis, and liver decompensation. Conclusion There is a continued rise in the proportion of non-obese NAFLD among hospitalizations in the US. Nonobese NAFLD hospitalizations were less likely to have hypertension and diabetes, but more likely to have decompensated liver disease. Further studies are needed to better characterize these patients to enable early detection, treatment, and reduction in complications of liver disease.